Clinico‐pathological characteristics of p63 expression in B‐cell lymphoma

• Published in: Cancer science Vol. 97; no. 10; pp. 1050 - 1055
• Main Authors: Fukushima, Noriyasu, Satoh, Toshimi, Sueoka, Naoko, Sato, Akemi, Ide, Masaru, Hisatomi, Takashi, Kuwahara, Nobuo, Tomimasu, Rika, Tsuneyoshi, Naoko, Funai, Noriko, Sano, Masayuki, Tokunaga, Osamu, Sueoka, Eisaburo
• Format: Journal Article
• Language: English
• Published: Melbourne, Australia Blackwell Publishing Asia 01-10-2006; Blackwell
• Subjects: Adult; Aged; Aged, 80 and over; Alternative Splicing; Biological and medical sciences; DNA-Binding Proteins - analysis; DNA-Binding Proteins - genetics; Female; Hematologic and hematopoietic diseases; Humans; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma, B-Cell - diagnosis; Lymphoma, B-Cell - mortality; Lymphoma, B-Cell - pathology; Male; Medical sciences; Middle Aged; Original; Prognosis; RNA, Messenger - analysis; Trans-Activators - analysis; Trans-Activators - genetics; Transcription Factors; Tumor Suppressor Proteins - analysis; Tumor Suppressor Proteins - genetics; Tumors; Human; Cancerology; Prognosis; Lymphoproliferative syndrome; Genetics; Malignant hemopathy; B-Lymphocyte; Gene expression; Non Hodgkin lymphoma
• ISSN: 1347-9032; 1349-7006
• DOI: 10.1111/j.1349-7006.2006.00284.x

A member of the family of p53‐related genes, p63 plays a role in regulating epithelial proliferation and differentiation programs, but the pathological and clinical meaning of p63 in B‐cell lymphoma has not been elucidated. We investigated the expression pattern of p63 in B‐cell malignancies, and evaluated the correlation between the expression of p63 and other germinal center markers. Ninety‐eight B‐cell lymphomas (28 FCL, 5 MCL, and 65 DLBCL) were analyzed by immunohistochemical examination for p63, bcl‐6, CD10 and MUM‐1 proteins, and for rearrangement of bcl‐2/IgH. Expression of p63 was observed in the nuclei of tumor cells obtained from 15 of 28 (54%) FCL, 22 of 65 (34%) DLBCL, but none of 5 MCL. In DLBCL, the expression of p63 and bcl‐6 showed a significant correlation (P < 0.02), but no correlation was observed between p63 and expression of CD10, MUM‐1, or bcl‐2/IgH rearrangement. RT‐PCR revealed that TAp63α‐type transcripts, a possible negative regulator of transcriptional activation of p21 promoter, were major transcripts in B‐cell lymphoma tissues. As for prognostic significance, only patients in the p63 positive group of FCL died, and in the non‐germinal center group, the p63 positive cases appeared to have inferior overall survival than other groups in DLBCL. Our preliminary results suggested that p63 expression is a disadvantageous factor for prognosis in this subgroup of B‐cell lymphomas. (Cancer Sci 2006; 97: 1050–1055)